Does Empagliflozin Modulate Leukocyte–Endothelium Interactions, Oxidative Stress, and Inflammation in Type 2 Diabetes?

Does Empagliflozin Modulate Leukocyte–Endothelium Interactions, Oxidative Stress, and Inflammation in Type 2 Diabetes?

Sodium-glucose co-transporter 2 inhibitors (iSGLT2) have been linked to cardiovascular risk reduction in patients with type 2 diabetes (T2D). However, their underlying molecular mechanisms remain unclear. This study aimed to evaluate the effects of empagliflozin, a novel potent and selective iSGLT-2...

Full description

Bibliographic Details
Main Authors: Francisco Canet, Francesca Iannantuoni, Aránzazu Martínez de Marañon, Pedro Díaz-Pozo, Sandra López-Domènech, Teresa Vezza, Blanca Navarro, Eva Solá, Rosa Falcón, Celia Bañuls, Carlos Morillas, Milagros Rocha, Víctor M. Víctor
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Antioxidants
Subjects:
cardiovascular risk
empagliflozin
inflammation
oxidative stress
type 2 diabetes
Online Access:https://www.mdpi.com/2076-3921/10/8/1228

Internet

https://www.mdpi.com/2076-3921/10/8/1228

Similar Items